J&J wins FDA label expansion for fourth U.S. indication

by
Contributor since / Followers

1 week ago

Johnson & Johnson (NYSE:JNJ) has received FDA approval for its bowel disease therapy Tremfya for Crohn’s disease, a chronic inflammatory disorder of the gastrointestinal tract, marking it the drug???s fourth U.S.-approved indication.
Accordingly, the antibody therapy designed to block a proinflammatory

Tags: JNJ